Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Maryam Ghashghaei"'
Autor:
Maryam Ghashghaei, Yilin Liu, James Ettles, Giuseppe Bombaci, Niveditha Ramkumar, Zongmin Liu, Leo Escano, Sandra Spencer Miko, Yerin Kim, Joseph A. Waldron, Kim Do, Kyle MacPherson, Katie A. Yuen, Thilelli Taibi, Marty Yue, Aaremish Arsalan, Zhen Jin, Glenn Edin, Aly Karsan, Gregg B. Morin, Florian Kuchenbauer, Fabiana Perna, Martin Bushell, Ly P. Vu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)
Abstract Protein synthesis is frequently deregulated during tumorigenesis. However, the precise contexts of selective translational control and the regulators of such mechanisms in cancer is poorly understood. Here, we uncovered CNOT3, a subunit of t
Externí odkaz:
https://doaj.org/article/70b7701b4c0b40d88cc303cdcb9178b8
Autor:
Maryam Ghashghaei, Yilin Liu, James Ettles, Giuseppe Bombaci, Niveditha Ramkumar, Zongmin Liu, Leo Escano, Sandra Spencer Miko, Yerin Kim, Joseph A. Waldron, Kim Do, Kyle MacPherson, Katie A. Yuen, Thilelli Taibi, Marty Yue, Aaremish Arsalan, Zhen Jin, Glenn Edin, Aly Karsan, Gregg B. Morin, Florian Kuchenbauer, Fabiana Perna, Martin Bushell, Ly P. Vu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/0f59f076c7fc4285a49794e5de178a16
Autor:
Maryam Ghashghaei, Cong Truc Le, Haya Shaalan, Leo Escano, Marty Yue, Aaremish Arsalan, Arefeh Rouhi, Tuan Anh Nguyen, Ly Phuong Vu
Publikováno v:
Blood Advances.
Regulation of gene expression at the RNA level is an important regulatory mechanism in cancers. However, post-transcriptional molecular pathways underlying tumorigenesis remain largely unexplored. In this study, we uncovered a functional axis consist
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dfec223b99beda4f6c4baef9f3408da
https://doi.org/10.1182/bloodadvances.2022008123
https://doi.org/10.1182/bloodadvances.2022008123
Autor:
Maryam Ghashghaei, Marty Yue, Aaremish Arsalan, Giuseppe Bombaci, Sandra Spencer Miko, Haya Shaalan, Glenn Edin, Gregg Morin, Fabiana Perna, Ly P Vu
Publikováno v:
Blood. 140:2962-2963
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71dbaa626981a15d5fd6b8d96cbdd0d0
https://doi.org/10.1182/blood-2022-163026
https://doi.org/10.1182/blood-2022-163026
Autor:
Ghashghaei, Maryam, Liu, Yilin, Ettles, James, Bombaci, Giuseppe, Ramkumar, Niveditha, Liu, Zongmin, Escano, Leo, Miko, Sandra Spencer, Kim, Yerin, Waldron, Joseph A., Do, Kim, MacPherson, Kyle, Yuen, Katie A., Taibi, Thilelli, Yue, Marty, Arsalan, Aaremish, Jin, Zhen, Edin, Glenn, Karsan, Aly, Morin, Gregg B.
Publikováno v:
Nature Communications; 10/7/2024, Vol. 15 Issue 1, p1-1, 1p
Autor:
Tamim Niazi, Celia M. T. Greenwood, Thierry Muanza, Mark Basik, Adriana Aguilar-Mahecha, Kathleen Oros Klein, Maryam Ghashghaei
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
Scientific Reports
Scientific Reports
Prostate cancer (PCa) is the most common cancer amongst men. A novel androgen receptor (AR) antagonist, enzalutamide (ENZA) has recently been demonstrated to enhance the effect of radiation (XRT) by impairing the DNA damage repair process. This study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddcfd260dd82595589cfb119f7d3110c
http://link.springer.com/article/10.1038/s41598-019-44991-w
http://link.springer.com/article/10.1038/s41598-019-44991-w
Autor:
Ly Vu, Aaremish Arsalan, Guiseppe Bombaci, Glenn Edin, Lina Garawany, Maryam Ghashghaei, Sandi Miko, Gregg Morin, Fabiana Perna, Marty Yue
Publikováno v:
Experimental Hematology. 111:S154
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7d282496a30382a16890897356b7f53
https://doi.org/10.1016/j.exphem.2022.07.275
https://doi.org/10.1016/j.exphem.2022.07.275
Autor:
Miltiadis Paliouras, M. Heravi, Hamed Bekerat, Mark Trifiro, Thierry Muanza, Tamim Niazi, Maryam Ghashghaei
Publikováno v:
The Prostate. 78:64-75
Background Prostate cancer (PCa) is a progressive disease and the most diagnosed cancer in men. The current standard of care for high-risk localized PCa is a combination of androgen deprivation therapy (ADT) and radiation (XRT). The majority of these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1040c569a81bb0f6577c4b0b6d3bce65
https://doi.org/10.1002/pros.23445
https://doi.org/10.1002/pros.23445
Autor:
Mohammad Tamim Niazi, Thierry Muanza, Moulay A. Alaoui-Jamali, Maryam Ghashghaei, Miltiadis Paliouras
Publikováno v:
Cancer Research. 78:858-858
Prostate cancer treatment is based on the estimated risk of recurrence in the U.S. Combined androgen deprivation therapy (ADT) with radiation therapy (XRT) is the standard of care for high-risk localized PCa. However, a large percentage of tumors are
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::984b97a6eb82b472b39927e423e2f139
https://doi.org/10.1158/1538-7445.am2018-858
https://doi.org/10.1158/1538-7445.am2018-858
Publikováno v:
Journal of Clinical Oncology. 35:208-208
208 Background: Prostate cancer is the second leading cause of cancer-related deaths amongst men in North America. Data suggests that, following radiation therapy (XRT), androgen receptor (AR) enhances DNA damage repair and contributes to resistance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e548fff4a49339cc9d8b20e5cb9ffd42
https://doi.org/10.1200/jco.2017.35.6_suppl.208
https://doi.org/10.1200/jco.2017.35.6_suppl.208